Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Name: Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
Published: 2013
License: Public Domain

GlaxoSmithKline · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

chronic-obstructive copd efficacy pulmonary-disease safety

pulmonary disease, chronic obstructive, long acting beta2- receptor agonist, long acting muscarininc receptor antagonist, dry powder inhaler, safety, copd, inhaled corticosteroid, efficacy, fluticasone furoate/vilanterol, umeclidinium bromide, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Related documents